Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06927999 · ClinicalTrials.gov registry record · Phase 2
An Outpatient Study of the Efficacy of ARS-2 in Patients With Chronic Spontaneous Urticaria
A Phase 2 study of Urticaria Chronic, sponsored by ARS Pharmaceuticals.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 42
- Enrollment target
- 3
- Study locations
NCT06927999: Recruiting Phase 2 study of Urticaria Chronic, sponsored by ARS Pharmaceuticals.
NCT06927999 is a Phase 2 study of Urticaria Chronic that is actively recruiting participants, run by ARS Pharmaceuticals. The registered enrollment target is 42 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (68% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06927999, a Phase 2 study of Urticaria Chronic, is actively recruiting participants, sponsored by ARS Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 42 participants
- Enrollment target
- 3
- Study locations
Study Summary
This is a Phase 2b, outpatient, single-dose, randomized, double blind, placebo-controlled, three period crossover study that will consist of a screening period and three blinded treatment periods. Subjects enrolled will have CSU with a history of moderate to severe acute exacerbations (or flares).
Primary Outcome
Change in itch and hive scores (Uniform Assessment System) \[UAS\] as compared to placebo at each timepoint on exacerbation days
Conditions Studied
Interventions
- DRUG Placebo
- DRUG 0.5 mg epinephrine
- DRUG 1 mg epinephrine
Study Locations (3)
Illinois
- Endeavor Health Clinical Trials Center - Glenview
Ohio
- Bernstein Clinical Research Center, LLC - Cincinnati
Other
- Institute of Allergology IFA Charité - Campus Benjamin Franklin | Hindenburgdamm 30 - Berlin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2025-07-09 |
| Est. Completion | 2026-06 |
| Phase | Phase 2 |
What NCT06927999 shows while recruiting
NCT06927999 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 42 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (68% lower).
The record links to 1 condition, with Urticaria Chronic appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT06927999 reports a single indexed study location in Illinois, Ohio, Other.
Frequently Asked Questions
What is clinical trial NCT06927999 about?
NCT06927999 is a clinical study titled "An Outpatient Study of the Efficacy of ARS-2 in Patients With Chronic Spontaneous Urticaria". This is a Phase 2b, outpatient, single-dose, randomized, double blind, placebo-controlled, three period crossover study that will consist of a screening period and three blinded treatment periods. Subjects enrolled will have CSU with a history of moderate to severe acute exacerbations (or flares).
What is the current status of trial NCT06927999?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 42 participants. The study started on 2025-07-09. Estimated completion is 2026-06.
What conditions does trial NCT06927999 study?
This clinical trial studies the following conditions: Urticaria Chronic.
What interventions are being tested in trial NCT06927999?
The interventions under investigation include: Placebo (DRUG), 0.5 mg epinephrine (DRUG), 1 mg epinephrine (DRUG).
Who is sponsoring clinical trial NCT06927999?
This trial is sponsored by ARS Pharmaceuticals, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06927999 being conducted?
This trial has 3 study locations across Illinois, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Urticaria Chronic
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06927999's enrollment target sits among peer trials
42 1339th of 2000 higher than 649 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02852213 · 42 participants · Phase 1
A Single-Stage, Adaptive, Open-label, Dose Escalation Safety and Efficacy Study of AADC Deficiency in Pediatric Patients
- NCT03136146 · 42 participants · Phase 2
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia
- NCT03178149 · 42 participants · Phase 1
A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration
- NCT03663530 · 42 participants · NA
Circadian Misalignment and Energy Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI